島 俊英 しま としひで 先生

来歴等

略歴

1983年 京都府立医科大学卒
1983年 京都府立医科大学附属病院研修医(第３内科)
1985年 京都市立病院研修医 (内科，麻酔科)
1986年 京都府立医科大学附属病院修練医(第３内科)
1990年 大阪府済生会吹田病院内科医員
1992年 米国ダートマス大学EPR研究所研究員
1994年 星ヶ丘厚生年金病院内科医長
1996年 大阪府済生会吹田病院内科医長
2002年 同院　消化器内科部長
2014年 同院　副院長
2020年 同院　院長

論文

1. Shima T, Uto H, Ueki K, et al. Clinicopathological features of liver injury in patients with type 2 diabetes mellitus and comparative study of histologically proven nonalcoholic fatty liver diseases with or without type 2 diabetes mellitus. J Gastroenterol. 2013; 48: 515-525.
2. Shima T, Seki K, Umemura A, et al. Influence of lifestyle-related diseases and age on the development and progression of non-alcoholic fatty liver disease. Hepatol Res. 2015; 45: 548-559.
3. Okanoue T, Shima T, Hasebe C, et al. Long-term follow up of peginterferon-α-2a treatment of hepatitis B e-antigen (HBeAg) positive and HBeAg negative chronic hepatitis B patients in phase II and III studies. Hepatol Res. 2016; 46: 992-1001.
4. Yoshimura K, Okanoue T, Ebise H, Iwasaki T, Mizuno M, Shima T, Ichihara J, Yamazaki K. Identification of novel noninvasive markers for diagnosing nonalcoholic steatohepatitis and related fibrosis by data mining. Hepatology. 2016; 63: 462-473.
5. Toyoda H, Kumada T, Tada T, Shimada N, Takaguchi K, Senoh T, Tsuji K, Tachi Y, Hiraoka A, Ishikawa T, Shima T, Okanoue T. Efficacy and tolerability of an IFN-free regimen with DCV/ASV for elderly patients infected with HCV genotype 1B. J Hepatol. 2017; 66: 521-527.
6. Mizuno M, Shima T, Oya H, et al. Classification of patients with nonalcoholic fatty liver disease using rapid immunoassay of serum type IV collagen compared with that using liver histology and other fibrosis markers. Hepatol Res. 2017; 47: 216-225.
7. Seki K, Shima T, Oya H, et al. Assessment of transient elastography in Japanese patients with non-alcoholic fatty liver disease. Hepatol Res. 2017; 47: 882-889.
8. Kawaguchi T, Shima T, Mizuno M, et al. Risk estimation model for nonalcoholic fatty liver disease in the Japanese using multiple genetic markers. PLoS One. 2018; 13(1): e0185490.
9. 高橋 彩, 島 俊英, 木下 直彦, 他. HCV初発肝癌の発見契機におけるdirect-acting antivirals（DAA）治療の臨床的意義. 日本消化器病学会雑誌　2018; 115: 184-194.
10. Shima T, Uto H, Ueki K, et al. Hepatocellular carcinoma as a leading cause of cancer-related deaths in Japanese type 2 diabetes mellitus patients. J Gastroenterol. 2019; 54: 64-77.
11. Shima T, Sakai K, Oya H, et al. Diagnostic accuracy of combined biomarker measurements and vibration-controlled transient elastography (VCTE) for predicting fibrosis stage of non-alcoholic fatty liver disease. J Gastroenterol. 2020; 55: 100-112.
12. Okanoue T, Shima T, Mitsumoto Y, et al. Artificial intelligence/neural network system for the screening of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Hepatol Res. 2021; 51: 554-569.
13. Okanoue T, Shima T, Mitsumoto Y, et al. Novel artificial intelligent/neural network system for staging of nonalcoholic steatohepatitis. Hepatol Res. 2021; 51: 1044-1057.
14. Shima T, Ohtakaki Y, Kikuchi H, et al. A novel rapid immunoassay of serum type IV collagen 7S for the diagnosis of fibrosis stage of nonalcoholic fatty liver diseases. Hepatol Res. 2021; 51: 263-276.
15. Kinoshita N, Shima T, Terasaki K, et al. Comparison of thrombocytopenia between patients with non-alcoholic fatty liver disease and those with hepatitis C virus-related chronic liver disease. Hepatol Res. 2022 May 11. doi: 10.1111/hepr.13791.
16. 島 俊英, 片山　貴之, 光本　保英, 他. NAFLD/NASHの非侵襲的診断法(NIT). 消化器内科2022; 4(2): 59-67.
17. 島　俊英. 特集　１ページでわかる内科疾患の診療ノート　非アルコール性脂肪性肝疾患・非アルコール性脂肪肝炎. 内科 2022; 129(4): 860-862.